Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Faculdade de Medicina do ABC
Modality
UNKNOWN
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01043913CT.gov Guarana (Paullinia Cupana) for Breast Cancer Chemotherapy-related Fatigue | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Characteristic
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Guarana Extract (this asset) | Faculdade de Medicina do ABC | P2 | B · 57 |
| Risperidone | National Institute of Mental Health and Neuro Sciences, India | P4 | BB |
| Citalopram | National Institute of Mental Health and Neuro Sciences, India | P4 | BB |
| Vortioxetine | Northwell Health | P4 | BB |
| Bradanicline | Targacept Inc. | P2 | B |
| Azacitidine | Institute of Hematology & Blood Diseases Hospital, China | P2 | CCC |
| Daunomycin | Institute of Hematology & Blood Diseases Hospital, China | P2 | CCC |
| Cytarabine | Institute of Hematology & Blood Diseases Hospital, China | P2 | CCC |
| Venetoclax | Institute of Hematology & Blood Diseases Hospital, China | P2 | CCC |
+3 more in the Disease Characteristic cohort
Other indications for Guarana Extract
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Disorder | — | P2 | B · 57 |
| Neoplasm | — | P2 | CCC · 51 |
| Breast Neoplasm | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Guarana Extract in Disease Characteristic. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/guarana-extract-disease-characteristic
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →